In addition, antibody-drug conjugates (ADC) provided a further improvement not only in progression-free survival (PFS) but also in overall survival (OS) in advanced HER2-positive breast carcinoma [7,8]. This evidence concerns the gene ERBB2 and breast carcinoma.